Provided by Tiger Trade Technology Pte. Ltd.

Biogen

216.65
-1.8500-0.85%
Post-market: 219.002.35+1.08%17:06 EDT
Volume:830.99K
Turnover:180.42M
Market Cap:31.99B
PE:38.48
High:218.89
Open:216.47
Low:213.58
Close:218.50
52wk High:222.85
52wk Low:133.53
Shares:147.64M
Float Shares:147.31M
Volume Ratio:1.48
T/O Rate:0.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.63
EPS(LYR):8.79
ROE:4.58%
ROA:5.21%
PB:1.70
PE(LYR):24.65

Loading ...

Biogen Inc. Stock Slips 8.2%, Underperforms Peers

Dow Jones
·
Jul 15

IBM, Goldman Sachs, SK Hynix, Micron, Crowdstrike, Biogen, and More Stocks That Explain Today's Market

Dow Jones
·
Jul 15

Cantor Fitzgerald Adjusts Biogen Price Target to $237 From $206

MT Newswires Live
·
Jul 15

Biogen Stock Sinks on Lackluster Alzheimer's News

Dow Jones
·
Jul 14

RBC says Biogen detailed Phase 2 results ‘leave more questions than answers’

TIPRANKS
·
Jul 14

Biogen to face questions on safety and dose response, says Stifel

TIPRANKS
·
Jul 14

Eisai, Biogen announce presentation of results from real-world LEADER study

TIPRANKS
·
Jul 14

Leqembi® Real-world Leader Study Presented at Aaic® 2026 Finds over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved over an Average of 17 Months of Treatment

THOMSON REUTERS
·
Jul 14

Movement Alert|Biogen Falls 7.06% in Regular Trading, Diranersen Phase 2 CELIA Full Data Reveals Missed Primary Endpoint Sparking Registration Path Concerns

Market Focus
·
Jul 14

Biogen Down over 7%, on Pace for Largest Percent Decrease Since November 2020

Dow Jones
·
Jul 14

Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and TG Therapeutics (TGTX)

TIPRANKS
·
Jul 14

Biogen Shares Down 6.2% After Co's Experimental Alzheimer's Drug Misses Main Goal in Mid-stage Study

THOMSON REUTERS
·
Jul 14

Biogen announces expanded data from CELIA study evaluating diranersen

TIPRANKS
·
Jul 14

Biogen Plans Phase 3 Development of Alzheimer’s Tau Therapy Diranersen After Phase 2 Data

Reuters
·
Jul 14

Biogen - to Advance Diranersen into Confirmatory Phase 3 Development

THOMSON REUTERS
·
Jul 14

Biogen - Diranersen Shows 50–65% Mean Reduction in Csf Total Tau and Brain Tau Pathology

THOMSON REUTERS
·
Jul 14

Biogen Presents Phase 2 Celia Data at Aaic Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

THOMSON REUTERS
·
Jul 14

Biogen's Alzheimer's Drug Lowers Toxic Protein, but Results were Mixed

Reuters
·
Jul 14

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD)

TIPRANKS
·
Jul 14

Piper Sandler Remains a Buy on Biogen (BIIB)

TIPRANKS
·
Jul 14